<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="phosphate, zanamivir, laninamivir and peramivir, of which oseltamivir phosphate and" exact="zanamivir" post="are the two currently licensed NAI drugs used for"/>
 <result pre="NAI drugs used for the treatment and prophylaxis of influenza4;" exact="peramivir" post="is licensed for use in the United States of"/>
 <result pre="States of America5. Recently resistance to the NAIs oseltamivir and" exact="zanamivir" post="was reported among H5N1 viruses isolated in India6. Due"/>
 <result pre="vitro and in vivo studies20. It was shown that after" exact="amantadine" post="addition in cell cultures infected with susceptible HPAI H5N1"/>
 <result pre="there was an absolute reduction in HA titres, whereas the" exact="amantadine" post="resistant viruses, which possessed the molecular signatures required for"/>
 <result pre="In the study by Wang et al20, the antiviral drug" exact="ribavirin" post="was administered via the albumen route, while the virus"/>
 <result pre="was inoculated via the allantoic route. It was found that" exact="ribavirin" post="administered in the albumen of the egg is detectable"/>
 <result pre="the last decadeScientifica (Cairo)2014201443062924800107 8HurtACLowtherSMiddletonDBarrIGAssessing the development of oseltamivir and" exact="zanamivir" post="resistance in A(H5N1) influenza viruses using a ferret modelAntiviral"/>
 <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res200462374515026200 18HaydenGGBruntonLLLazoJSParkerKLAntiviral agents (Non-retroviral)Goodman and Gilman's -"/>
</results>
